Given that GLUT4 is highly abundant in skeletal muscle and is associated with enhanced glucose disposal and insulin action, there has been extensive interest in therapeutic strategies to increase AKT and GLUT4 expression in cohorts at risk of developing metabolic disorders [39, 40]. This evidence concerns the gene SLC2A4 and metabolic disease.